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Introduction: Replacement of the missing clotting factor is the mainstay of haemophilia 
treatment. Whilst historically many haemophilia patients were infected with blood-borne vi-
ruses transmitted via plasma-derived products, nowadays the formation of alloantibodies 
against the missing clotting factor is the main adverse event of treatment.  
Areas covered: This paper provides an overview of the current national and international 
adverse event reporting systems, what these surveillance schemes taught us about side effects 
of the products presently in use, and elaborates on how to adapt these systems to the challeng-
es we face with the changing treatment landscape. 
Expert commentary: Treatment of inherited bleeding disorders was accompanied by severe 
complications in the past, resulting in major morbidity and mortality. Current products are 
much safer, but still require monitoring via efficient safety surveillance systems. Adverse 
events are reported in national and international systems. With many new products entering 
the market, as well as non-factor replacement therapies, new safety issues may arise. It is im-
portant to identify potential adverse events early by making surveillance systems suitable to 
pick up unknown or unexpected effects, and to recognize and communicate patterns of ad-









Safety surveillance is important in identifying, evaluating and communicating treatment-
related adverse events as early as possible. This is particularly important for a life-long dis-
ease like haemophilia, with a history of severe treatment-related complications. 
Haemophilia is an inherited bleeding disorder, affecting around 400.000 individuals world-
wide. The X-linked inheritance results in deficiency of clotting factor VIII (FVIII) in haemo-
philia A and of FIX in haemophilia B. Haemophilia represents the most well-known inherited 
bleeding disorder, a group of which also includes deficiency or defect of fibrinogen, FII, FV, 
FVII, FXI, FXIII, and von Willebrand factor, as well as platelet disorders. Lack of FVIII or 
FIX results in impaired thrombin generation and clot formation, which clinically translates 
into spontaneous or traumatic bleeding. 
 
1.1 Clotting factor concentrates 
The mainstay of haemophilia treatment is the replacement of the deficient clotting factor. 
Initially, fresh frozen plasma was used, but later specific concentrates were produced from 
plasma pools, followed by the development of recombinant factors. The introduction of 
recombinant products in the early 1990s changed haemophilia management greatly with 
prophylactic treatment becoming the standard of care in patients with severe haemophilia 
(<1% clotting factor activity). This dramatically improved health outcomes and life-
expectancy for haemophilia patients. Table 1 shows the currently available clotting factor 
concentrates. Treatment can be given ‘on demand’, i.e. at time of a bleed, or ‘prophylactic’ to 
prevent bleeding [1]. 
 
2. Treatment complications 
2.1 Viral transmission 
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The unfortunate contamination of blood products in the past has left a heavy legacy of 
concerns about safety of treatment for haemophilia. Cryoprecipitate and plasma-derived 
concentrates introduced respectively in the 1960s and 1970s resulted in transmission of 
hepatitis C (HCV) and human immunodeficiency virus (HIV). Plasma-derived products, each 
batch of which was manufactured from pools of 20.000 to 30.000 blood donations, were 
associated with a 30% risk of HIV [2], and 46%-90% of HCV infection [3, 4, 5]. These 
infections can lead to major and significant complications: 20% of HCV infected patients 
develop cirrhosis, and progression to end-stage liver disease is accelerated by coinfection with 
HIV [6]. This had major impact on survival of haemophilia patients, especially before the 
introduction of effective antiretroviral therapies [2]. 
Viral inactivation steps for plasma-derived products [7], and the introduction of recombinant 
products (with third generation recombinant products being manufactured without the use of 
any animal or human plasma protein additives during the entire process) [8], have eliminated 
the risk of HIV and HCV transmission. On the other hand, concern remains for the possible 
transmission by plasma-derived products of parvovirus B19, Creutzfeldt-Jakob disease, hepa-
titis E, as well as for a number of new pathogens (West Nile, Zika, Dengue) and currently 
unknown agents [9]. 
 
2.2 Inhibitors 
At present, the most important adverse event of haemophilia treatment is the development of 
alloantibodies, rapidly eliminating the infused exogenous factor, thus reducing or neutralizing 
the concentrate efficacy. This occurs in around 30% of patients with severe FVIII deficiency 
(highest risk within the initial 50 exposure days) and in about 3-4% of severe FIX deficiency 
patients [10]. In previously treated patients (PTPs) the incidence of inhibitor development is 
much lower (1-5 per 1000 patient/years) [11] (table 2). Once a patient develops a high-titer 
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inhibitor, the available treatment is with one of two bypassing agents (activated prothrombin 
complex concentrate (aPCC) and recombinant FVIIa (rFVIIa)) or with recombinant porcine 
FVIII. 
The pathophysiology of inhibitor development and the different risk factors have been exten-
sively studied [12, 13, 14, 15]. Several risk factors are identified in previously untreated pa-
tients (PUPs) (family history, gene defects, intensity of treatment), whilst for PTPs the risk 
factors for antibody development remain unknown [15]. 
The antigenic properties of different concentrates remain matter of investigation. Among 
PUPs, a number of observational retrospective/prospective studies and systematic reviews 
[16, 17, 18, 19] investigated the rate of inhibitor development in plasma-derived and 
recombinant products, generating conflicting results. Variables such as study design, study 
periods, therapeutic indications and other methodologic factors complicate the interpretation 
of the results. The most recent study in this field is SIPPET, a randomized controlled trial 
prospectively comparing plasma-derived and recombinant products, that reports a higher 
immunogenicity of recombinant products [14], opening a debate on the best treatment 
approach for PUPs.  
Differences in the rate of inhibitor development among different generations of recombinant 
products constitutes another current debate. The RODIN study [18] showed a higher rate of 
inhibitor development in PUPs with severe haemophilia A treated with a specific second-
generation product. This was also found in two other cohort studies [20, 21]. Analysis of data 
from the multicenter European Haemophilia Safety Surveillance (EUHASS) registry, after 
excluding overlapping data with the aforementioned studies [18, 20, 21], did not demonstrate 
differences in inhibitor development according to concentrate in PUPs [22, 23]. The 
Pharmacovigilance Risk Assessment Committee of the European Medicine Agency (EMA) 
performed a meta-analysis of the published studies and concluded that the currently available 
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evidence does not support the perceived increased risk of inhibitors associated with some 
specific recombinant FVIII products [24]. 
Although it had been suggested that in PTPs a B-domain deleted recombinant FVIII product 
was associated with a higher inhibitor risk [25], this was not confirmed in a subsequent meta-
analysis [26]. 
There are many new treatments for haemophilia currently under development, and 
particularly non-factor replacement strategies could help in reducing the risk of inhibitor 
development, by eliminating the exposition to exogenous factor replacement. 
 
2.3 Thrombogenicity 
Although patients with inherited bleeding disorders suffer from bleeding, and evidence sug-
gests that they are relatively protected from thrombosis [27, 28], both arterial and venous 
thromboses do occur, especially after abolishing the relative protection by replacing the defi-
cient clotting factor. Data from a systematic review confirmed that the risk of thromboembol-
ic adverse events is low, with an overall prevalence of 3.6 per 1000 patients [29]. Superficial 
thrombophlebitis accounted for 18 of the 20 reported thrombotic adverse events, but two ma-
jor venous thromboembolic episodes occurred, both in patients with von Willebrand disease 
related to surgery. Risk factors for thrombosis were prolonged replacement in case of severe 
bleeding or major surgery, or co-existing risk factors (age, estrogen intake, obesity), and high 
peak FVIII levels. In patients with central venous access devices, the rate of thrombosis-
related complications was 10.8% [29]. Administration of bypassing agents (aPCC, rFVIIa) in 
haemophilia patients with high-titer inhibitors is also considered as an important trigger for 
thrombosis [30, 31]. 
Although the risk of thrombotic adverse events after clotting factor administration is low, as 
the life expectancy of haemophilia patients and comorbidities increases the risk of thrombosis 
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is likely to raise accordingly in future [32]. Finally, as factor concentrate consumption grows 
over time, ongoing surveillance is essential.  
 
2.4 Allergic reactions and minor adverse events 
Anaphylaxis after concentrate infusion is extremely rare, but minor allergic reactions repre-
sent the most common non-thrombotic, non-inhibitor adverse events associated with haemo-
philia treatment. A systematic review of all prospective registration studies in patients with 
haemophilia A identified only a single anaphylactic episode in the last 20 years [33]. The 
overall number of adverse events was 732, with 240 allergic reactions reported, including site-
reactions, nausea, vomiting and headache. No difference between plasma-derived or recombi-
nant products in terms of adverse event association was reported [33].  
On the whole, the total rate of adverse events was calculated at 0.13%, confirming the high 
degree of safety of the products currently used for replacement therapy. 
Specific for haemophilia B is the occurrence of allergic and anaphylactic reactions to FIX 
concentrate infusion occurring at time of inhibitor development [34]. The exact pathophysio-
logic mechanism is unclear, it occurs more frequently in patients with a large deletion in the 
FIX gene, but overall the incidence is low. 
 
3. Current adverse event reporting in haemophilia 
3.1 Adverse events during clinical trials 
Adverse events, however minor, are formally reported during clinical trials used for registra-
tion purposes. Such studies are performed at good clinical practice (GCP) standard and the 
problem for the clinician is that so many events are reported that it is difficult to know which 
are the important ones. Once a drug is marketed the manufacturer has to perform post-




3.2 Generic national schemes 
Many countries have generic schemes by which doctors, other health professionals and often 
patients can report adverse events for any medicinal product [9]. In the UK the scheme is 
known as the yellow form scheme, named after the color of the form used for submission of 
the adverse event information. The information initially provided is brief but the reporting 
individual subsequently receives a request asking for much more information that is often 
time consuming to complete. Often the enthusiasm for reporting to this scheme wanes once 
the first report has been submitted. 
 
3.3 Specialized haemophilia national schemes 
National schemes for reporting adverse events exist in the UK, France, Netherlands, Italy, 
Canada, USA and Australia [9]. These schemes vary in the detail of the information collected 
and the length of time they have been in existence. Although traditionally the regulatory au-
thorities depended on clinical trials for adverse event reporting, there is a move that could 
result in registry data being accepted in the future [35]. 
The UK Haemophilia Centre Doctors Organisation (UKHCDO) scheme is the most developed 
and has been in existence for almost thirty years. The scheme is particularly strong in the re-
porting of inhibitors and deaths and has resulted in a number of high impact publications [2, 
21, 36, 37, 38, 39]. The quality of the data is based on the fact that the UK has a good quality 
registry of all patients with inherited bleeding disorders and all their treatments that has been 
running since 1968. Clinicians in the UK report inhibitors, thromboses, malignancies, deaths 
as well as all treatments with concentrate.  
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In France, the FranceCoag network collects high quality data on inhibitor development in all 
patients with haemophilia [20]. The reported data are checked by auditors that visit the centers 
to confirm the accuracy of the information.  
In the Netherlands, the KWARK system collects prospective adverse events, but no publica-
tions have so far been sought. Most Dutch haemophilia centers also participate in internation-
al adverse event reporting efforts such as RODIN and EUHASS. 
Canada has adopted four years ago a system very similar to EUHASS, called CHESS, which 
actually uses the same software infrastructure (CHESS). The intention is to combine CHESS 
and EUHASS data in the future, taking advantage of the similarities of their process. 
In the USA the ATHN collaboration is collecting data on the treatment of patients with inher-
ited bleeding disorders, including adverse events but so far nothing has been reported on the 
adverse event. Important publications from previous collaborative studies in the US coordi-
nated from the Centre for Disease Control have been published [40, 41, 42]. 
 
3.4 Specific multicenter schemes 
a) RODIN  
The RODIN (Research Of Determinants of Inhibitor Development) study is being carried 
out by the PEDNET group. In the RODIN registry patients with haemophilia are registered 
at diagnosis and followed up to their 75th exposure day. The participating centers are main-
ly in Europe with some centers in Canada and Israel. Among the important publications 
from this study were a report suggesting that one second generation recombinant FVIII 
concentrate was associated with a higher rate of inhibitors [18, 43], and papers on the risk 
factors for inhibitor development in PUPs [44, 45]. In terms of adverse events the RODIN 




The European Haemophilia Safety Surveillance (EUHASS) was set up in 2008 to monitor 
adverse events in the treatment of inherited bleeding disorders in Europe. Currently 85 
haemophilia centers from 26 European countries are participating. Events are reported as 
they occur or by three months at the latest, and centers have to confirm that they have not 
had any events, if this is the case. Annually each haemophilia center reports on the number 
of patients with the different types of bleeding disorders and also on the number of patients 
treated with each specific concentrate. All bleeding disorders and all concentrates are in-
cluded in EUHASS [9, 46, 47]. Table 3 shows the type of events reported in EUHASS, and 
table 4 shows the events reported up to 10th October 2016. 
 
4. Future perspectives 
The haemophilia treatment landscape is evolving rapidly, with many new products entering 
the market or being well along in the pharmaceutical pipeline (see table 5). Whilst it is clear 
that these developments hold promise to answer currently unmet medical needs, information 
on their long-term safety is limited. It is unlikely that large trials comparing these products 
head-to-head will be performed and as such, data from well-designed and well-managed reg-
istries will be an important source to assess efficacy and safety of different treatment modali-
ties in a real world setting [48]. 
 
4.1 Potential new infectious agents 
The risk of transmission of infectious agents decreased drastically by improvements in the 
process of purification and viral inactivation of concentrates. Third-generation recombinant 
products are manufactured without human or animal proteins other than the required factor in 
the culture medium or final formulation [8]. However, non-enveloped viruses still represent a 
potential risk by resisting viral inactivation techniques as demonstrated by the continued 
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transmission of parvovirus B19 through plasma-derived factor concentrates [49]. Another 
emerging small non-enveloped virus is hepatitis E (HEV), with an IgG seroprevalence up to 
30% in Irish male blood donors over 60 years [50]. RNA positivity was detected in 0.02-0.1% 
of blood donations tested, with the highest incidence in South Asian countries [50, 51, 52]. 
There are indications that viral inactivation procedures during fractionation are able to clear 
HEV [53]. Nevertheless, HEV is a small non-enveloped virus, which lends itself to some level 
of removal by nanofiltration.  
Other potential threats are West Nile, Dengue, Ross River, Zika virus, and currently unknown 
agents [54], indicating the need for continued surveillance.  
 
4.2 Extended half-life products 
A number of new treatment options are promising to introduce a new era for haemophilia 
care. In order to reduce the frequency of infusion, extended half-life products are becoming 
available with the first products currently licensed, and many others in the pipeline [55, 56]. 
Different technologies are used to prolong the circulation of recombinant factors, including 
fusion to recombinant albumin or to the Fc-region of human IgG, attachment of polyethylene 
glycol (PEG), polysialylated FVIII, and single chain FVIII. These products are equally effica-
cious in treating acute bleeds and show a good short-term safety [57]. Long-term safety of 
these modified molecules needs to be monitored, and uncertainty remains about the immuno-
genicity of these products. Theoretically, these modifications could diminish the immunogen-
icity via inducing B-cell anergy, tolerance, or masking immunogenic epitopes [58], but 
whether this outweighs the high immunogenic potential of FVIII in the long-term remains 
unanswered. For PEG, although assumed to be non-immunogenic, naturally-occurring anti-
bodies are detected in up to 25% of healthy donors [59] and these antibodies may accelerate 
clearance and compromise therapeutic efficacy [60, 61].  
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PEGylation could also potentially lead to new issues, since PEG is a chemical compound that 
cannot be readily metabolized. It might lead to accumulation in the liver with unknown toxi-
cological consequences. Whereas clinical trials with limited follow-up are reporting reassur-
ing results, the lifelong nature of the disease and treatment makes it important to register and 
record outcomes longitudinally. The introduction of new molecules also introduces the risk of 
unknown side effects, which prompts to adapt the report systems to ensure that they will pick 
up these events. 
 
4.3 Alternative therapeutic strategies 
A number of technologies attempt to improve hemostasis by mechanisms other than replacing 
the missing factor. A bispecific antibody specifically binding factor IX and X and mimicking 
the cofactor activity of FVIII (ACE910) has been produced and is injected subcutaneously 
[62]. Other approaches exploit the inhibition of natural anticoagulants [55, 63, 64], for in-
stance via a monoclonal antibody (mAb) targeting tissue factor pathway inhibitor (TFPI) [65], 
a mAb blocking the interaction between FX and TFPI [66], or RNA interference therapeutic 
targeting antithrombin [67]. These technologies may prevent inhibitor development, and pro-
vide a mechanism for reducing or eliminating exposure to the deficient factor. In addition, 
reduction of dose frequency and subcutaneous administration of treatment may represent a 
real breakthrough in the routine management of haemophilia. However, inhibiting natural 
anticoagulants carries the risk of inducing a hypercoagulable state and therewith thrombosis, 
particularly during rescue treatment with FVIII or FIX. If and when these products are li-
censed, they will require specific safety monitoring. 
 
4.4 Gene therapy 
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Ultimately, gene therapy and gene editing have the potential of curing the disease. Small in-
creases in factor activity levels are potentially sufficient to improve the disease phenotype and 
therefore have a significant clinical impact, especially for resource-limited countries. The first 
gene therapy studies were carried out in haemophilia B, as the FIX gene is considerably 
smaller than the FVIII gene. It remains a matter of debate as to what factor level to aim for 
prevention of joint bleeds without increasing the risk of thrombosis. Moreover, the duration of 
the therapeutic effect has to be awaited, with currently reported consistent increased levels at 
a follow-up of 4.5 years [68].  
A new strategy to achieve higher sustained levels is the use of a naturally occurring gain-of-
function mutated FIX gene (FIX-Padua) that has a ~8-fold greater FIX activity [69]. The first 
preliminary results in 4 patients showed an increase of FIX activity to 25-35% with a follow-
up of 7-26 weeks [70]. Furthermore, a clinical trial is being planned in haemophilia B to in-
vestigate the possibility of gene editing by inserting an not mutated copy of the FIX gene into 
the hepatocytes using a zinc finger protein [71].  
For haemophilia A, the first gene therapy study is currently running, with interim results 
demonstrating FVIII levels >15% in all patients treated with the high dose [72]. In 4 of these 
7 patients, levels were >50% at the latest evaluation (7-23 weeks), which raises the concern of 
thrombogenicity.  
Other potential risks of gene therapy are toxicity, inflammatory responses, hepatitis, and in-
sertional mutagenesis. As the effects of a single infusion are potentially everlasting, it also 
raises the question what time of follow-up is sufficient to state that it is a safe therapy. For this 
treatment modality, special registries need to be designed as safety follow-up for at least a 
portion of the patients is likely to be lifelong.  
 
4.5 Registry design 
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At present, there is a large number of registries with different aims and designs. Registries 
often focus on different aspects of the disease or treatment and collect different types of data. 
Whereas it is clear that monitoring in registries is useful, the growing number of registries 
might come at the expense of overall data quality. Ideally, every patient should be in a regis-
try with a specific patient identifier to avoid overlap and reduce double counting. To ensure 
consistency across participating sites and registries, data elements should be clearly defined, 
and changes in definitions over time need to be recorded. For the design of a registry, it is 
necessary to identify, in advance, potential adverse events and how and when they should be 
reported. The same holds true for new unexpected events. As most registries try to include as 
many data elements as possible, the workload increases, with the risk of high rates of discon-
tinuation and missing data. By clearly defining the purpose of the registry and limiting the 
number of items that can be reported, the quality of the registry will improve and missing data 
decrease. 
 To improve quality during data collection, consistent registration over time and between par-
ticipating sites should be reassured. Standardized training should be provided for all registry 
personnel. Systematic and frequent data registration is important to prevent recall bias, which 
requires dedicated (research) personnel and time. To improve outcome from registry data, it is 
important to consider this during the design phase and obtain sufficient financial support. 
At last, a central body should be responsible for surveillance of data and registration, admin-
istration and interpretation of the provided data. Registries are of most value if they com-
municate findings via regular reports. 
 
4.6 Electronic medical records and diaries 
Electronic medical records will play an increasingly important role as data source for regis-
tries. Structured data like ICD-10 diagnoses and laboratory results can already be collected 
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automatically. Data extraction of free text is more labor intensive, but new technologies like 
‘natural language processing’ [73] may facilitate this, reducing workload and potential human 
errors. 
Moreover, electronic patient diaries are used increasingly to record treatment and bleeds. 
With the introduction of hand-held devices, patients can record data anywhere, anytime. Alt-
hough adherence to record keeping is still a problem, data from an electronic diary can more 
easily be verified and connected to registries. 
 
4.7 Rapid alert systems 
An important task of registries is to recognize adverse effects of treatment and to act accord-
ingly. It is important to recognize adverse effects rapidly, and to notify the community imme-
diately if a severe or unexpected adverse event has been reported. 
 
5. Expert commentary 
Safety surveillance is an important issue in all diseases and treatments, but specifically in in-
herited bleeding disorders, as these patients were disproportionally affected by adverse events 
in the past. Inherited bleeding disorders are rare diseases, adverse events in their treatment 
even more rare, and the number of treatment modalities increasing. It is therefore important to 
collaborate in monitoring adverse events. Creating a network of treatment centers who collab-
orate in reporting adverse events has the advantage of recognizing adverse event patterns rap-
idly and notifying the community if any safety issue arise. To ascertain commitment to report 
long-term and completeness of data, a balance between quantity and quality in the number of 
parameters and registries must be found. Harmonization and transparency of registries is nec-




6. Five-year view 
In the next few years interfacing registries with electronic medical records and electronic dia-
ries will become more important. This will pose new issues in confidentiality, privacy, securi-
ty, and data access. 
With the introduction of new treatment modalities, especially non-replacement strategies and 
gene therapy, it is likely that new types of adverse events will occur. Registries need to be 
adapted to this challenge, to ensure that unknown side effects will be picked up. Post-
marketing surveillance will serve as an important data source to compare efficacy and safety 
of the new treatment modalities. Long-term surveillance is imperative to warrant the safety of 
treatment in haemophilia, as the past has taught us that safety needs to be confirmed rather 
than assumed. 
 
7. Key issues 
 The mainstay of haemophilia treatment is to prevent bleeding and its sequelae by 
replacement of the deficient clotting factor. 
 In the past, major morbidity occurred due to transmission of viral infections by 
plasma-derived concentrates. 
 At present, the most important adverse event in haemophilia treatment is the de-
velopment of alloantibodies (inhibitors).  
 Prospective adverse event reporting in (inter)national registries is essential to mon-
itor treatment safety and efficacy in inherited bleeding disorders. 
 In the future, surveillance systems need to be adapted to monitor the safety of new 
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Table 1. Currently available clotting factor concentrates 
Clotting factor Plasma-derived concentrates Recombinant concentrate 
Fibrinogen Yes No 
II Yes (as PCC) No 
VII Yes Yes 
VIII Yes Yes 
VIII – porcine No Yes 
VIII-EHL No Yes (Fc fusion; PEGylated) 
IX Yes Yes 
IX-EHL No Yes (Fc fusion; albumin fu-
sion) 
X Yes No 
XI Yes No 
XIII Yes Yes 
VWF Yes Yes 






Table 2. Risk of inhibitor development according to the number of exposure days (EDs) 
Exposition to factor concentrates Risk of inhibitor development 
PUPs Previously untreated patients:  
no previous exposure to factor 
concentrates 
  
High risk – first 50 exposure days 
MTPs Minimally treated patients:   
< 3 – 5 exposure days * 
PTPs Previously treated patients:  
> 50-150  exposure days * 
Low risk  –  more than 50 exposure days 





Table 3. Adverse events reported in the EUHASS scheme 
Allergic and other acute events 





Unexpected poor efficacy 





Table 4. Adverse events reported to EUHASS by 10th October 2016  
Event type Number reported 
Allergic and other acute events 153 
Transfusion transmitted infections 0 
Inhibitors – first occurrence 380 
Inhibitors – recurrence  46 
Thromboses 172 
Malignancies  446 





Table 5. Therapies in development 
Therapy Route of administration Status of clinical trial 
Plasma-derived FV Intravenous In vitro 
PEGylated FVIII Intravenous Phase 3 
PEGylated FIX Intravenous Phase 3 
Antibody against TFPI Subcutaneous Phase 1 
siRNA against AT Subcutaneous Phase 1/2  
Bispecific antibody against 
FIXa and FX 
Subcutaneous Phase 1/2 
FVIII gene therapy Intravenous Phase 1/2 
FIX gene therapy Intravenous Phase 1/2 
FIX gene editing Intravenous Phase 1 
AT, antithrombin; siRNA, silencing RNA; TFPI, tissue factor pathway inhibitor 
